Assenagon Asset Management S.A. Acquires Shares of 530,618 Supernus Pharmaceuticals, Inc. $SUPN

Assenagon Asset Management S.A. acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 1st quarter, HoldingsChannel reports. The institutional investor acquired 530,618 shares of the specialty pharmaceutical company’s stock, valued at approximately $27,428,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Campbell Newman Asset Management Inc. lifted its position in Supernus Pharmaceuticals by 1.7% in the first quarter. Campbell Newman Asset Management Inc. now owns 44,808 shares of the specialty pharmaceutical company’s stock valued at $2,316,000 after purchasing an additional 738 shares during the last quarter. SG Americas Securities LLC lifted its position in Supernus Pharmaceuticals by 2,847.0% in the 1st quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock valued at $19,498,000 after acquiring an additional 364,413 shares in the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at $237,000. Finally, Sit Investment Associates Inc. lifted its holdings in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 250 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday. Finally, Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 23rd. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $46.84 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $30.93 and a 12 month high of $59.68. The company has a market capitalization of $2.72 billion, a PE ratio of -91.84, a P/E/G ratio of 0.96 and a beta of 0.55. The firm’s 50-day moving average is $47.47 and its 200 day moving average is $49.47.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.